Diagnostics, Research reagents for Antiphospholipid Syndrome

Endotelix Diagnostics Ltd. specializes in the development of innovative diagnostic tools and treatments for Antiphospholipid Syndrome (APS), an autoimmune disorder characterized by thrombosis and pregnancy complications. The company offers a range of products designed for clinical management of APS, including a standardized anti-B2GP1 IgG ELISA test for both human and mouse samples. This diagnostic tool is aimed at providing fast, reliable, and specific results, which are crucial for early diagnosis and effective patient care.

In addition to their current offerings, Endotelix is actively working on future developments, including an APS mimic IgG that possesses the pathogenic properties of IgG found in APS patients. This focus on innovation underscores the company's commitment to enhancing the understanding and management of APS through advanced diagnostic solutions and therapeutic options. Their pipeline reflects a dedication to improving clinical outcomes for patients affected by this complex syndrome.

Switzerland

Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies.

Endotelix Diagnostics Ltd

Company Details